TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24365208

Group type: EXPERIMENTAL
Intervention: Intramuscular ergometrine (0.5mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular oxytocin (10 IU)
Number of subjects: 0
Study: 22810989

Group type: EXPERIMENTAL
Intervention: Margarine fortified with EPA (10 weight percent)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Margarine fortified with DHA (10 weight percent)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Margarine fortified with ALA (10 weight percent)
Number of subjects: 74
Study: 20799900

Group type: EXPERIMENTAL
Intervention: Chair massage (n=40)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Relaxation control (n=42)
Number of subjects: 82
Study: 18639450

Group type: EXPERIMENTAL
Intervention: Irinotecan (IRI), Leucovorin (LV), and bolus 5-fluorouracil (5FU) administered weekly (80 mg/m2 IV IRI, 200 mg/m2 LV, 450 mg/m2 bolus 5FU) for six cycles followed by pelvic irradiation plus 5FU.
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control group: Leucovorin (LV) and bolus 5-fluorouracil (5FU) (200 mg/m2 LV and 450 mg/m2 IV bolus 5FU) for six cycles followed by pelvic irradiation plus 5FU.
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Irinotecan (IRI) arm
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 321
Study: 15947501

Group type: EXPERIMENTAL
Intervention: Combination of acetyl‐L‐carnitine, n‐3 fatty acids, and coenzyme Q10 (Phototrop)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 12757966

Group type: EXPERIMENTAL
Intervention: 2 mg sublingual buprenorphine tablets administered four times a day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 10496704

Group type: EXPERIMENTAL
Intervention: Split-tip, high-flow polyurethane catheter (MedComp AshSplit 14.5 F)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional silicone catheter (Bard Hickman 13.5 F)
Number of subjects: 24
Study: 8998896

Group type: EXPERIMENTAL
Intervention: Cemented total hip arthroplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cementless total hip arthroplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cemented acetabular components
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cementless sockets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cemented femoral component
Number of subjects: 0
Study: 1707646

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of enalapril and sulindac
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6957156

Group type: EXPERIMENTAL
Intervention: gemfibrozil (Lopid)
Number of subjects: 0
Study: 30420616

Group type: EXPERIMENTAL
Intervention: 3 months (3M) adjuvant chemotherapy
Number of subjects: 6088

Group type: COMPARATOR
Intervention: 6 months (6M) adjuvant chemotherapy
Number of subjects: 6088
Study: 27465309

Group type: EXPERIMENTAL
Intervention: Contamination-focused exposure therapy (3 sessions of 30 minutes each)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Contamination-focused exposure therapy
Number of subjects: 34
Study: 24273218

Group type: EXPERIMENTAL
Intervention: Whole soy (40 g soy flour)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Purified daidzein (63 mg)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Low-fat milk powder (placebo)
Number of subjects: 270
Study: 22941466

Group type: EXPERIMENTAL
Intervention: ADAM8 positive tumors
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: ADAM8 expression
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Serum levels of ADAM8
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: ADAM8 protein expression in tissues
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Correlation with clinicopathological parameters
Number of subjects: 126
Study: 20635286

Group type: EXPERIMENTAL
Intervention: REMAS intervention in psychosocial outpatient treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: REMAS intervention in methadone programs
Number of subjects: 0

Group type: COMPARATOR
Intervention: HIV education control condition
Number of subjects: 0
Study: 18979163

Group type: EXPERIMENTAL
Intervention: Teriparatide 20-microg
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Teriparatide 40-microg
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 16521631

Group type: EXPERIMENTAL
Intervention: Parnaparin 6400 IU subcutaneously once daily for 7 days
Number of subjects: 897

Group type: COMPARATOR
Intervention: Unfractionated heparin (IV bolus of 5000 IU followed by infusion of 800 to 1000 IU/hour for 48 hours, then 5000 IU subcutaneously every 6 hours for 5 days)
Number of subjects: 897

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: Parnaparin 6400 IU
Number of subjects: 897
Study: 12670809

Group type: EXPERIMENTAL
Intervention: Non-opioid regimen (ketorolac, clonidine, lidocaine, ketamine, magnesium sulfate, methylprednisolone)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fentanyl and non-opioid
Number of subjects: 30
Study: 10790000

Group type: EXPERIMENTAL
Intervention: Ritalin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8681660

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (800 micrograms beclomethasone dipropionate)
Number of subjects: 0
Study: 1992412

Group type: EXPERIMENTAL
Intervention: Amoxicillin, 500 mg three times daily for 14 days
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 108
Study: 6650445

Group type: EXPERIMENTAL
Intervention: Sodium phytate (equivalent to 2% phytic acid based on the starch portion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium phytate (added to unleavened bread)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High phytate bread
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium (added to reverse the effect of phytic acid)
Number of subjects: 0
Study: 31470410

Group type: EXPERIMENTAL
Intervention: Subdural drainage (cohort A)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Subgaleal drainage (cohort B)
Number of subjects: 361
Study: 29579024

Group type: EXPERIMENTAL
Intervention: Cleft Palate Simulator
Number of subjects: 10
Study: 28204607

Group type: EXPERIMENTAL
Intervention: Deltoid administration of aripiprazole once-monthly 400 mg (single-dose)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Deltoid administration of aripiprazole once-monthly 400 mg (multiple-dose)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Gluteal administration of aripiprazole once-monthly 400 mg (single-dose)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Gluteal administration of aripiprazole once-monthly 400 mg (multiple-dose)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Deltoid and gluteal administration of aripiprazole once-monthly 400 mg
Number of subjects: 173
Study: 26523029

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (50 min of walking followed by stretching exercises, 3 times a week for 12 weeks)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (IG)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Stretching exercises (CG)
Number of subjects: 70
Study: 23715094

Group type: EXPERIMENTAL
Intervention: Autism spectrum disorders group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Typically developing group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 21603892

Group type: EXPERIMENTAL
Intervention: alprazolam (1 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 19100012

Group type: EXPERIMENTAL
Intervention: Tongxinluo therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 80
Study: 17238402

Group type: EXPERIMENTAL
Intervention: Natural Language Processing system for automatic extraction of medical problems from clinical free-text documents
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 105
Study: 12814463

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 10626971

Group type: EXPERIMENTAL
Intervention: Biobrane
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1% silver sulfadiazine
Number of subjects: 20
Study: 9356558

Group type: EXPERIMENTAL
Intervention: Personal therapy
Number of subjects: 151

Group type: COMPARATOR
Intervention: Family therapy
Number of subjects: 151

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 151
Study: 8182269

Group type: EXPERIMENTAL
Intervention: Finger-stick assay for anti-HAV using whole blood on paper discs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified HAVAB method
Number of subjects: 0
Study: 3542088

Group type: EXPERIMENTAL
Intervention: Inhalation of dry cold air (causing significant bronchoconstriction)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Methacholine test without prior cold air inhalation
Number of subjects: 12
Study: 29848147

Group type: EXPERIMENTAL
Intervention: Seltorexant 40 mg for five days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 27320368

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 27647059

Group type: EXPERIMENTAL
Intervention: Warm handoff
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fax referral
Number of subjects: 100
Study: 22360575

Group type: EXPERIMENTAL
Intervention: EPs 7630 (3 × 10 drops/day for ages 1-6 years, 3 × 20 drops/day for ages >6-12 years, 3 × 30 drops/day for ages >12-18 years)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 20308694

Group type: EXPERIMENTAL
Intervention: Comprehensive multinutrient supplement (SUPP)
Number of subjects: 12
Study: 18341416

Group type: EXPERIMENTAL
Intervention: Conventional Raman spectroscopy with Mahalanobis distance, spectral residuals, and limit test methodology
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal ovarian tissues
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Malignant ovarian tissues
Number of subjects: 15
Study: 15739035

Group type: EXPERIMENTAL
Intervention: Alendronate (Aln, 10 mg/day) plus Raloxifene (Rlx, 60 mg/day)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Alendronate (Aln, 10 mg/day) plus Hormone Replacement Therapy (HRT, 0.625 mg/day conjugated equine estrogens plus 2.5 mg/day medroxyprogesterone acetate)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Alendronate (Aln) alone
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) alone
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Raloxifene (Rlx) alone
Number of subjects: 1100
Study: 11994888

Group type: EXPERIMENTAL
Intervention: Rivastigmine 3-12 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Risperidone 0.5-2 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Co-administration of rivastigmine and risperidone
Number of subjects: 90
Study: 10349921

Group type: EXPERIMENTAL
Intervention: Vecuronium administered with sevoflurane 2% (group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vecuronium administered with sevoflurane 2% after 30 min (group 3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vecuronium administered with sevoflurane 2% after 60 min (group 4)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 40
Study: 8602306

Group type: EXPERIMENTAL
Intervention: Depot goserelin, 3.6 mg subcutaneous implant given monthly
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Danazol, 200 mg two times per day
Number of subjects: 60
Study: 1760910

Group type: EXPERIMENTAL
Intervention: Senna tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium picosulphate powder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no bowel preparation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Senna tablets and Sodium picosulphate powder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laxatives (general)
Number of subjects: 0
Study: 6109500

Group type: EXPERIMENTAL
Intervention: Almitrine (1.5 mg/kg over a period of one hour)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no respiratory analeptic)
Number of subjects: 20
Study: 31087640

Group type: EXPERIMENTAL
Intervention: Hypofractionated whole breast radiotherapy (HF‐WBRT)
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Guideline publications
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Chemotherapy and/or tumour bed boost radiotherapy (TBBR)
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Individual clinicians
Number of subjects: 1171
Study: 28748002

Group type: EXPERIMENTAL
Intervention: High serum folate concentrations (>45.3 nmol/L)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: High serum folate concentrations
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Vitamin B12 concentrations
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Folic acid fortification
Number of subjects: 249
Study: 25547776

Group type: EXPERIMENTAL
Intervention: HD-tDCS
Number of subjects: 8

Group type: COMPARATOR
Intervention: CS-tDCS
Number of subjects: 8
Study: 24228854

Group type: EXPERIMENTAL
Intervention: Monday to Saturday rehabilitation (additional Saturday rehabilitation comprising physiotherapy and occupational therapy)
Number of subjects: 996

Group type: COMPARATOR
Intervention: Usual care Monday to Friday rehabilitation
Number of subjects: 996
Study: 17473036

Group type: EXPERIMENTAL
Intervention: Tobacco use quitline
Number of subjects: 82

Group type: COMPARATOR
Intervention: Brief counseling
Number of subjects: 82
Study: 14977577

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients (RA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients (RA) aged 45-55 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients (RA) aged 55 years and older
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RA patients treated with prednisone
Number of subjects: 0
Study: 10792560

Group type: EXPERIMENTAL
Intervention: HRT (2 mg oestradiol valerate for the first 3 months with the addition of 10 mg medroxyprogesterone for 10 days every third month thereafter)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 9422466

Group type: EXPERIMENTAL
Intervention: Real-time feedback of body center of gravity during postural training (visual feedback)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No feedback (NFB) group
Number of subjects: 0
Study: 8312288

Group type: EXPERIMENTAL
Intervention: ARREST intervention (three 90-minute sessions)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 87
Study: 3018228

Group type: EXPERIMENTAL
Intervention: ketocyclazocine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: cyclazocine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: morphine
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 31486356

Group type: EXPERIMENTAL
Intervention: Breakfast skipping (no breakfast)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Breakfast consumption (three-meal condition)
Number of subjects: 9
Study: 30095022

Group type: EXPERIMENTAL
Intervention: Vitamin D2 supplement 40,000 IU/week
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 27318427

Group type: EXPERIMENTAL
Intervention: Teen Outreach Program (TOP)
Number of subjects: 7976

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 7976
Study: 24528693

Group type: EXPERIMENTAL
Intervention: Fatty fish diet (n = 11)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lean fish diet (n = 12)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control diet (n = 10)
Number of subjects: 33
Study: 22410658

Group type: EXPERIMENTAL
Intervention: Topical 0.25% timolol maleate gel
Number of subjects: 23

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 23
Study: 19156926

Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (tumor-free patients)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Repeat surgeries
Number of subjects: 24
Study: 17227902

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 50 mg/m2 every 28 days
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Topotecan 1.5 mg/m2 for 5 days every 21 days
Number of subjects: 474
Study: 15753495

Group type: EXPERIMENTAL
Intervention: Landiolol (0.3 mg.kg(‐1))
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Landiolol (0.1 mg.kg(‐1))
Number of subjects: 64

Group type: COMPARATOR
Intervention: Saline (Control Group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Landiolol (0.1 and 0.3 mg.kg(‐1))
Number of subjects: 64
Study: 11948832

Group type: EXPERIMENTAL
Intervention: NC100150 (between 0.75 and 6 mg of Fe/kg of body weight)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-dose NC100150
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: NC100150
Number of subjects: 9
Study: 9465799

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (400 micrograms intravenously every 8 hours four times)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study: 8556665

Group type: COMPARATOR
Intervention: Phone-call support from nurses
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Problem-solving counselling
Number of subjects: 293

Group type: COMPARATOR
Intervention: Phone-call support
Number of subjects: 293
Study: 2165899

Group type: EXPERIMENTAL
Intervention: Fluocortolone (15-30 mg)
Number of subjects: 48
Study: 366721

Group type: EXPERIMENTAL
Intervention: Benoxaprofen (300 mg on the first day followed by 100 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benoxaprofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unusual trial design (double-blind cross-over)
Number of subjects: 0
Study: 31870702

Group type: EXPERIMENTAL
Intervention: Sucrose administration
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 31185991

Group type: EXPERIMENTAL
Intervention: Psychological maltreatment (experienced by 766 participants, 76.6%)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Psychological distress
Number of subjects: 1000
Study: 28298393

Group type: EXPERIMENTAL
Intervention: 5‐wk very‐low‐calorie diet (VLCD; 500 kcal/d)
Number of subjects: 61

Group type: COMPARATOR
Intervention: 12‐wk low‐calorie diet (1250 kcal/d)
Number of subjects: 61
Study: 26092673

Group type: EXPERIMENTAL
Intervention: Endovascular cooling using femoral devices (Icy catheter, Coolgard, Zoll)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Basic external cooling using fans, a homemade tent, and ice packs
Number of subjects: 400
Study: 23050490

Group type: EXPERIMENTAL
Intervention: CAF + CM
Number of subjects: 45

Group type: COMPARATOR
Intervention: CAF alone
Number of subjects: 45
Study: 21061103

Group type: EXPERIMENTAL
Intervention: TCD biofeedback (visual feedback of flow velocities in the middle cerebral arteries)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: TCD biofeedback (increase signal group)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: TCD biofeedback (decrease signal group)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: TCD biofeedback
Number of subjects: 22
Study: 19562559

Group type: EXPERIMENTAL
Intervention: Dinoprostone (Propess) application
Number of subjects: 141
Study: 17343275

Group type: EXPERIMENTAL
Intervention: Unilateral pallidotomy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of the subthalamic nucleus
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Rasagiline
Number of subjects: 61

Group type: COMPARATOR
Intervention: Other interventions
Number of subjects: 61
Study: 16366740

Group type: EXPERIMENTAL
Intervention: Herbal supplement containing 600 mg black tea extract (60% polyphenols, 20% caffeine) and 442 mg guarana extract (36% caffeine)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 16
Study: 11297904

Group type: EXPERIMENTAL
Intervention: 600 mg CQ
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 150 mg CQ
Number of subjects: 36
Study: 9623442

Group type: EXPERIMENTAL
Intervention: Tactile assessment of the train‐of‐four (TOF) count and TOF ratio by nursing staff
Number of subjects: 30

Group type: COMPARATOR
Intervention: TOF-Watch (acceleromyographic monitor)
Number of subjects: 30
Study: 7892366

Group type: EXPERIMENTAL
Intervention: Semantic orientation tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Explicit memory tests
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implicit memory tests
Number of subjects: 0
Study: 3283227

Group type: EXPERIMENTAL
Intervention: Betaxolol, 20 mg/day
Number of subjects: 17

Group type: COMPARATOR
Intervention: Verapamil, 240‐480 mg/day
Number of subjects: 17
Study: 29471185

Group type: EXPERIMENTAL
Intervention: Attention Training Technique (ATT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 101

Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 101
Study: 27719677

Group type: EXPERIMENTAL
Intervention: Community health workers' knowledge and practice regarding pre-eclampsia identification and treatment
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Training and equipment availability for community health workers
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Regular training and retraining for community health workers
Number of subjects: 34
Study: 24742190

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation (no-contact control group)
Number of subjects: 0